Wound Management Technologies Reports Record Preliminary Financial Results for the First Quarter of 2015 and Enhanced Sales Team

ADDISON, TX / ACCESSWIRE / April 22, 2015 / Wound Management Technologies, Inc. (OTCQB:WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX(R), today announced record preliminary financial and operating results for the first quarter of 2015 and additions to its sales management team.

Recent Financial Highlights

– Revenues increased 48% to $1.012 million for the first quarter 2015, compared to the first quarter 2014
– This follows year end 2014’s 52% growth to $2.633 million, compared to the prior year

Enhancing the Sales Management Team

In 2015 the Company began a new regional sales management strategy and is executing on its plan to phase in eight full-time regional sales managers by year end. The regional managers are responsible for both direct sales and working with the Company’s distributors. 

“We are excited to report that sales continue to grow leading us to a record high of over $1 million dollars in the first quarter. Besides growth in our wound care products line, our surgical product sales continue to grow as more and more surgeons are witnessing the tremendous efficacy of our products,” commented Robert Lutz, Jr. Chief Executive Officer.

“We are executing our strategy of building a highly-credentialed direct sales force to accelerate our sales and are pleased to announce the addition of Gordon McKenzie in South Florida and Craig Rose in Nashville, Tennessee as new Regional Sales Managers. Each of them has a strong sales management background and an exemplary track record of success in selling innovative science technologies. Craig and Gordon join Ken Snider as sales managers for the Company. This team will concentrate their efforts on direct hospital sales as well as continuing to develop, train and expand on our distributor relationships,” stated Mr. Lutz.

Earnings Call Scheduled for Today at 3 pm CST

The company previously announced it will conduct a quarterly earnings call on Wednesday, April 22, 2015 at 3:00 p.m. CST. Robert Lutz, Jr., CEO, will discuss first quarter 2015 results and provide and update on recent activities. A question and answer session will follow the presentation. Shareholders, analysts and other interested parties may join the call by dialing 1-712-775-7031 passcode 604070847# shortly before 3:00 p.m. CST.

About Wound Management Technologies

Wound Management Technologies, Inc. is an emerging commercial stage company with its primary products in the $5B worldwide advanced wound care market. Wound Management’s primary focus is the distribution of its Wound Care Innovations subsidiary’s unique, patented collagen product line, CellerateRX(R) which is FDA-cleared for all wound types except 3rd degree burns. The wound care product line is reimbursable under Medicare Part B and the surgical products are reimbursable as part of procedural billing. Wound Management has other advanced biotech products in development including a patented resorbable bone hemostat line that is in late stages of development. For more information visit www.wmgtech.com.

To download Wound Management Technologies’ investor relations app, which offers access to SEC documents, press releases, audio casts and more, please visit http://bit.ly/1zhNwnO to download on your iPhone and iPad or http://bit.ly/149PgWc for your Android mobile device.

Information about Forward-Looking Statements

The statements in the press release that relate to the Company’s expectations with regard to the future impact on the Company’s results from new products in development and any other statements not constituting historical facts are “forward-looking statements,” within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the Company’s actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company’s operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company’s SEC filings, which could cause the Company’s actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.

Investor Contacts:

Investor Relations
972.218.0935
info@wmgtech.com

SOURCE: Wound Management Technologies, Inc.

ReleaseID: 428074